SB 1214 Summary

• Authorizes pharmacists to independently order, perform, and interpret FDA-waived clinical laboratory improvement amendments tests for patients age 12+ with conditions including influenza, group A streptococcus pharyngitis, SARS-CoV-2, HIV pre/post-exposure prophylaxis, and emerging public health threats.

• Requires the Arizona State Board of Pharmacy to develop a statewide written protocol addressing documentation, records retention, patient screening, exclusion criteria, treatment instructions, follow-up care, and pharmacist training requirements.

• Mandates pharmacists use evidence-based clinical guidelines from the CDC, Infectious Diseases Society of America, or American Academy of Pediatrics for treatment decisions.

• Requires pharmacists to notify patients' primary care providers within 72 hours of initiating treatment and within 48 hours of any adverse reactions, and to maintain treatment records for seven years.

• Prohibits pharmacists from independently initiating opioid treatments or ordering tests for minors without written parental/guardian consent; establishes an advisory committee to develop protocols, repealing this committee provision on December 31, 2026.